Seasonal Allergic Rhinitis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Seasonal Allergic Rhinitis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Seasonal Allergic Rhinitis - Pipeline Review, H1 2015', provides an overview of the Seasonal Allergic Rhinitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Seasonal Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seasonal Allergic Rhinitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Seasonal Allergic Rhinitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Seasonal Allergic Rhinitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Seasonal Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Seasonal Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Seasonal Allergic Rhinitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Seasonal Allergic Rhinitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Seasonal Allergic Rhinitis Overview 7
Therapeutics Development 8
Pipeline Products for Seasonal Allergic Rhinitis - Overview 8
Pipeline Products for Seasonal Allergic Rhinitis - Comparative Analysis 9
Seasonal Allergic Rhinitis - Therapeutics under Development by Companies 10
Seasonal Allergic Rhinitis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Seasonal Allergic Rhinitis - Products under Development by Companies 13
Seasonal Allergic Rhinitis - Companies Involved in Therapeutics Development 14
Adamis Pharmaceuticals Corporation 14
FAES Farma SA 15
Glenmark Pharmaceuticals Ltd. 16
Merck & Co., Inc. 17
Mitsubishi Tanabe Pharma Corporation 18
Novartis AG 19
Ono Pharmaceutical Co., Ltd. 20
Shionogi & Co., Ltd. 21
VentiRx Pharmaceuticals, Inc. 22
Seasonal Allergic Rhinitis - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
(azelastine hydrochloride + mometasone furoate) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
(GSP 301-1 NS + GSP 301-2 NS) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
APC-3000 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
bepotastine besylate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
bilastine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
desloratadine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ONO-4053 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
S-555739 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
VAK-694 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
VTX-1463 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Seasonal Allergic Rhinitis - Recent Pipeline Updates 45
Seasonal Allergic Rhinitis - Dormant Projects 48
Seasonal Allergic Rhinitis - Discontinued Products 50
Seasonal Allergic Rhinitis - Product Development Milestones 51
Featured News & Press Releases 51
Oct 11, 2013: FDA Approves Sanofi's Nasacort Allergy 24HR for Over-the-Counter Use 51
May 01, 2012: Ista Reports Positive Phase II Trial Results Of BEPOSONE Nasal Spray 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Seasonal Allergic Rhinitis, H1 2015 8
Number of Products under Development for Seasonal Allergic Rhinitis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Seasonal Allergic Rhinitis - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 14
Seasonal Allergic Rhinitis - Pipeline by FAES Farma SA, H1 2015 15
Seasonal Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 16
Seasonal Allergic Rhinitis - Pipeline by Merck & Co., Inc., H1 2015 17
Seasonal Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 18
Seasonal Allergic Rhinitis - Pipeline by Novartis AG, H1 2015 19
Seasonal Allergic Rhinitis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 20
Seasonal Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H1 2015 21
Seasonal Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Assessment by Combination Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Seasonal Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H1 2015 45
Seasonal Allergic Rhinitis - Dormant Projects, H1 2015 48
Seasonal Allergic Rhinitis - Dormant Projects (Contd..1), H1 2015 49
Seasonal Allergic Rhinitis - Discontinued Products, H1 2015 50